According to foreign media reports, Pfizer will generate record-high revenue in 2022 and expect to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid this year.

    However, the company posted mixed fourth-quarter results, beating on earnings but missing on revenue. Pfizer’s stock was down more than 5.7% in morning trading.

    Pfizer CEO Albert Bourla said sales of Paxlovid could be higher than the company’s guidance, but the expectations are based on deals signed or close to being signed. Angela Hwang, head of biopharmaceuticals, said Pfizer is an active discussions with over 100 countries around the world on Paxlovid.

    About Pfizer

    Pfizer is an American multinational pharmaceutical and biotechnology corporation.

    On the ranking of “The 2nd Daguan·Keweiwei World Brand Value Top 900" released on January 13, 2022, Pfizer’s brand value was 1221.507 billion RMB, ranking the 6th.

Author:   Nan

Views:   651985